Protocol Ledger

NCT07671911 · Phase III · RECRUITING

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

Interventional Phase III clinical trial protocol NCT07671911 sponsored by Trevi Therapeutics in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-29 Enrollment: 306 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07671911
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)306 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07671911
Protocol FieldVerified Registry Value
NCT IdentifierNCT07671911
Consolidated Lead SponsorTrevi Therapeutics
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment306 participants (ESTIMATED)
Registered Start Date2026-06-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07671911
Hospital Research SiteLocationSite Profile
Montefiore Medical CenterThe Bronx, NYOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI